The initiation of coverage by Goldman Sachs, a major investment bank, can bring increased attention to Fulcrum Therapeutics. However, the neutral rating suggests that Goldman Sachs does not expect significant price movement in the short term. The price target of $5 provides a reference point for investors, but does not necessarily indicate a strong bullish or bearish sentiment.